Drug Trial Radar · NCT04480502
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
Last checked: Nov 19, 2026Latest source record: May 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
207
Actual
Start
Dec 9, 2020
Primary completion
Oct 2024
Study completion Oct 2024
Sponsor
- Lead sponsor
- Tracon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.
Conditions
- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
Interventions
EnvafolimabBiological
PD-L1 single domain antibody for subcutaneous injection.
IpilimumabDrug
CTLA-4 monoclonal antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) by RECIST 1.1 assessed by blinded independent central reviewTime frame: 40 months
Locations
30 sites in 2 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona
University of California, Los Angeles
Los Angeles, California
Sarcoma Oncology Research Center
Santa Monica, California
Stanford University
Stanford, California
University of Colorado
Aurora, Colorado
Mayo Clinic, Jacksonville
Jacksonville, Florida
University of Miami
Miami, Florida
H. Lee Moffitt Cancer Center
Tampa, Florida
Northwestern University
Evanston, Illinois
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University in St. Louis
St Louis, Missouri
Columbia University
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Duke University
Durham, North Carolina
University Hospitals
Cleveland, Ohio
Cleveland Clinic
Cleveland, Ohio
Ohio State University
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University (Sidney Kimmel Cancer Center)
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Vanderbilt University
Nashville, Tennessee
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Commonwealth University
Richmond, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
Medical College of Wisconsin
Wauwatosa, Wisconsin
Royal Marsden
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.